hERG-IN-3 

hERG-IN-3 is an orally active hERG blocker with an IC₅₀ of 44.5 nM. hERG-IN-3 exhibits a K_i for β2-adrenergic receptor of 14 nM. hERG-IN-3 exhibits the skeletal muscle Nav1.4 and sodium channel-blocking activities (IC₅₀ =4.4 μM, 3-fold increasement than hNav1.5). hERG-IN-3 displays a potent antimyotonic activity in an animal model. hERG-IN-3 can be used for the study of Myotonia Congenita^[1].

hERG-IN-3 exhibits affinity on α1A and β2 receptors with K_is of 270 and 14 nM^[1].
hERG-IN-3 exhibits relaxant activity of the tested compounds on K⁺-depolarized guinea pig longitudinal ileum smooth muscle with an IC₅₀ of 0.83 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

hERG-IN-3 (1 mg/kg, p.o., single dose) significantly improves muscle rigidity symptoms in rat myotonia model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

429.53

C₂₂H₂₇N₃O₄S

OC(COC1=CC=CC(O)=C1)CN2CCC(N(C3=NC4=CC=C(O)C=C4S3)C)CC2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cavalluzzi MM, et al. Hunting for lubeluzole analogues as antimyotonic agents with reduced cardiac liability. Eur J Med Chem. 2025 Nov 5;297:117964.  [Content Brief]